Did You Know...
...that when IBM conducted a market study of Chester Carlson's invention in 1959, the company concluded that it would take only 5000 units of his new product to saturate the market? IBM therefore declined to be part of the new product introduction. Too bad for IBM. Carlson's invention was the xerography process, and his new product was the beginning of the Xerox Corporation. It is estimated that every day, worldwide, 3,000,000,000 copies are made!!
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Number | Title | Issue Date |
| 7425547 | Nucleoside derivatives for treating hepatitis C virus infection Disclosed are compounds, compositions and methods for treating viral infections caused by a flaviviridae family virus, such as hepatitis C virus. Such compounds are represented by Formula IB as follows: and pharmaceutically... | 09/16/2008 |
| 7342003 | Synthesis of 2-aralkyloxyadenosines, 2-alkoxyadenosines, and their analogs Provided is a method for the synthesis of an aralkyloxyadenosine or an alkoxyadenosine. The method includes protecting the hydroxyl sugar groups with a protecting group to produce a protected halogenated adenosine. The protected halogenated adenosine is alkoxylated,... | 03/11/2008 |
| 7199127 | Purine nucleosides Disclosed are purine nucleoside compounds that are selective to A3 adenosine receptors and are useful for the treatment of cancer and inflammatory diseases. The compounds are shown by the following general formula (I), including isomers thereof: | 04/03/2007 |
| 7189706 | C2,5′-disubstituted and N,C2,5′-trisubstituted adenosine derivatives and pharmaceutical compositions containing them The present invention concerns novel C2,5′-disubstituted and N6,C2,5′-trisubstituted adenosine derivatives and their different uses. These adenosine derivatives were found to be potent adenosine receptor agonists and thus are of a therapeutic value in... | 03/13/2007 |
| 7183264 | N-pyrazole A2A receptor agonists 2-adenosine N-pyrazole compounds having the following formula: and methods for using the compounds as A2A receptor agonists to stimulate mammalian coronary vasodilatation for therapeutic purposes and for purposes... | 02/27/2007 |
| 7144872 | N-pyrazole Areceptor agonists This specification discloses 2-adenosine N-pyrazole compounds having the following formula: and methods for using the compounds as A2A receptor agonists to stimulate mammalian coronary vasodilatation for therapeu... | 12/05/2006 |
| 7141553 | A3AR agonists for the treatment of inflammatory arthritis The present invention concerns a method for the treatment of inflammatory arthritis, and in particular rheumatoid arthritis, by administering to the subject specific low dosages of N6-(3-iodobenzyl)-adenosine 5′-N-methyl-uronamide (IB-MECA) and 2-chloro-N6-(3-iodo... | 11/28/2006 |
| 7112574 | C2,8-disubstituted adenosine derivatives and their different uses Novel C2,8-disubstituted adenosine derivatives disclosed herein have been found to be potent adenosine receptor agonists, in particular for the A2A receptor. The said compounds have biological activity against conditions such as hypertension, ischemic heart disease,... | 09/26/2006 |
| 7084127 | C2,5′-disubstituted and N, C2,5′-trisubstituted adenosine derivatives and their different uses The present invention concerns novel C2,5′-disubstituted and N6′,C2,5′-trisubstituted adenosine derivatives and their different uses. These adenosine derivatives were found to be potent adenosine receptor agonists and thus are of a therapeutic value... | 08/01/2006 |
| 6949640 | Method for synthesizing 2-chloro-9-(2-fluoro-β-D-arabinofuranosyl)-9H-purin-6-amine 2-Chloro-9-(2-deoxy-2-fluoro-β-D-arabinofuranosyl)-9H-purin-9-amine is synthesized by reacting a 2-chloro-6-substituted purine with a protected and activated 2-deoxy-2-fluoro-D-arabinofuranose; and reacting with a base such as ammonia to provide 2-chloro-9-(2-deoxy... | 09/27/2005 |
| 6946449 | Partial and full agonists of A1 adenosine receptors Disclosed are novel compounds that are partial and full A1 adenosine receptor agonists, useful for treating various disease states, in particular tachycardia and atrial flutter, angina, and myocardial infarction. ... | 09/20/2005 |
| 6921753 | Purine derivatives The present invention relates to compounds of the formula and pharmaceutically acceptable salts and solvates thereof, to processes for the preparation of, intermediates used in the preparation of, and compositions cont... | 07/26/2005 |
| 6914053 | Adenosine A3 receptor agonists Disclosed are novel adenosine A3 receptor agonists of Formula I: wherein: R is hydrogen or lower alkyl; R1 is optionally substituted lowe... | 07/05/2005 |
| 6900309 | Purine derivatives The present invention relates to compounds of the formula and pharmaceutically acceptable salts and solvates thereof, and to processes for the preparation of, intermediates used in the preparation of, compositions cont... | 05/31/2005 |
| 6803457 | Compounds for the treatment of ischemia A3 agonists, methods of using such A3 agonists and pharmaceutical compositions containing such A3 agonists. The A3 agonists are useful for the reduction of tissue damage resulting from tissue ischemia or hypoxia. ... | 10/12/2004 |
| 6680382 | Process for preparing purine nucleosides The present invention provides for the preparation ଲ-adenine nucleosides by coupling an adenine derivative containing an unprotected exocyclic amino group at the C-6 position and a blocked arabinofuranosyl derivative, in the presence of a base and s... | 01/20/2004 |
| 6677316 | Adenosine derivatives and methods of administration A method of treating a patient suffering from or susceptible to ischemic heart disease, peripheral vascular disease or stroke or which subject is suffering pain, a CNS disorder or sleep apnea which comprises administering a therapeutically effective amoun... | 01/13/2004 |
| 6642210 | 2-(N-pyrazolo)adenosines with application as adenosine A2A receptor agonists N-pyrazole substituted 2-adenosine compounds and methods for using the compounds as A2 A-adenosine receptor agonists useful to stimulate mammalian coronary vasodilation for therapeutic purposes and as adjuncts in cardiological imaging.... | 11/04/2003 |
| 6576620 | Method of identifying partial adenosine A1 receptor agonists The present invention provides a method for identifying partial adenosine A1 receptor agonists that are useful in the treatment of arrhythmias. Partial adenosine A1 receptor agonists and methods for using partial adenosine A1 receptor agonists to treat ar... | 06/10/2003 |
| 6544960 | Chemical compounds A compound of formula (I), wherein R2 represents C1-3 alkyl, halogen or hydrogen; R3 represents straight or branched alkyl group of 1-6 carbon atoms; with the proviso that, when R3 represents C1-3 alk... | 04/08/2003 |
| 6498241 | 2-deoxy-isoguanosines isosteric analogues and isoguanosine derivatives as well as their synthesis 2'-Deoxyisoguanosine, isosteric analogues and isoguanosine derivatives of formulae I-V, processes for their production via compounds of the general formulae a or b and reaction with aroyl isocyanates or from compounds of the general formulae VI-IX by phot... | 12/24/2002 |
| 6492348 | Adenosine derivatives A compound of formula (I) which is an agonist at the adenosine Al receptor, wherein Y, Z, and W represent heteroatoms, and salts and solvates thereof, in particular, physiologically acceptable solvates and salts thereof for use in therapy. ##STR1##... | 12/10/2002 |
| 6407076 | Adenosine analogues and related method of treatment A compound of formula (I) wherein R2 represents C1-3 alkyl, halogen or hydrogen; R3 represents a fluorinated straight or branched alkyl group of 1-6 carbon atoms; and salts and solvates thereof, in particular, physiologica... | 06/18/2002 |
| 6403567 | N-pyrazole A2A adenosine receptor agonists 2-adenosine N-pyrazole compositions having the following formula: ##STR1## and methods for using the compositions as A2A receptor agonists to stimulate mammalian coronary vasodilatation for therapeutic purposes and for purposes of imaging the heart.... | 06/11/2002 |
| 6355787 | Purine nucleoside modifications by palladium catalyzed methods and compounds produced This invention discloses a method for the preparation of 2'-modified nucleosides, using a palladium catalyst and an alkene functionalized with a heteroatom. Included in the invention are the novel pyrimidines and purines that can be prepared according to ... | 03/12/2002 |
| 6326359 | Adenosine A2A receptor agonists as antiinflammatory agents The present invention provides compounds of formula (I): ##STR1## and pharmaceutically acceptable salts and solvates thereof, together with processes for the preparation of, compositions containing, uses of and intermediates used in the preparation of suc... | 12/04/2001 |
| 6294522 | N6 heterocyclic 8-modified adenosine derivatives N6 heterocyclic 8 modified adenosine derivatives that are selective, partial or full adenosine A1 receptor partial or full agonists, and as such, are useful for modifying cardiac activity, modifying adipocyte function, treating centr... | 09/25/2001 |
| 6258793 | N6 heterocyclic 5' modified adenosine derivatives N6 heterocyclic 5' modified adenosine derivatives that are adenosine A1 receptor partial or full agonists, and as such, are useful for modifying cardiac activity, modifying adipocyte function, treating central nervous system disorder... | 07/10/2001 |
| 6252061 | Process for the production of 2-halo-6-aminopurine derivatives A novel process for preparing 2-halo-6-aminopurine derivatives and their analogs is disclosed. The method comprises halogenation of 2,6-diaminopurine derivatives at the C-2 position in a specific combination of aprotic polar and nonpolar organic solvents ... | 06/26/2001 |
| 6221851 | Pharmaceutical therapy for congestive heart failure The present invention is directed to reduce elevated levels of tumor necrosis factor-alpha (TNF-) found in a failing heart. The present invention is directed to a composition and method of regulating TNF- expression in myocardial tissue by t... | 04/24/2001 |
| 6180615 | Propargyl phenyl ether A2A receptor agonists 2-adenosine propargyl phenyl ether compositions having the following formula: ##STR1## and methods for using the compositions as A2A receptor agonists to stimulate mammalian coronary vasodilatation for therapeutic purposes and for purposes... | 01/30/2001 |
| 6093807 | Sugar-modified 7-deaza-7-substituted oligonucleotides Functionalized nucleomonomers and oligonucleotides are provided which have increased nuclease resistance and enhanced binding affinity to target DNA or RNA molecules. The oligonucleotides of the present invention comprise at least one 7-deaza-7-iodo-2'-su... | 07/25/2000 |
| 6020483 | Nucleoside modifications by palladium catalyzed methods This invention discloses a method for the preparation of 2'-modified nucleosides, using a palladium catalyst and an alkene functionalized with a heteroatom. Included in the invention are the novel pyrimidines and purines that can be prepared according to ... | 02/01/2000 |
| 5998388 | Adenosine derivatives This invention relates to novel adenosine derivatives, to processes for their preparation, to pharmaceutical compositions containing them and to their use in medicine. Thus the invention provides compounds of formula (I) which are agonists at the adenosin... | 12/07/1999 |
| 5994321 | Antiviral guanine analogs A series of guanine analogs and physiological salts thereof, which are useful as virus inhibitors and as antiviral agents in the treatment of viral disease, having the basic structures of: ##STR1## wherein B is H, CH3 or NH2 ; C... | 11/30/1999 |
| 5945524 | Process for the chemical synthesis of oligonucleotides Use of a dansylethoxycarbonyl group as base-labile 5'-hydroxyl protective group in the chemical synthesis of DNA and RNA and suitable synthetic processes. The ease of detection of the dansyl protective group and the ease of elimination from the sugar resi... | 08/31/1999 |
| 5942497 | Purine compound and catecholamine compound containing compositions and methods for administration A purine compound, which has a desired and an undesired effect when a dosage sufficient to induce the desired effect is administered to a mammal, is combined with a counteracting agent, wherein the counteracting agent can reduce the undesired effect when ... | 08/24/1999 |
| 5939543 | Stable solid 2-octynyl adenosine and process for producing the same The present invention provides two kinds of solid 2-octynyl adenosine products with novel properties which are stabilized with respect to temperature or temperature and humidity, one being solid 2-octynyl adenosine having a moisture content of not more th... | 08/17/1999 |
| 5817641 | Treatment of enterotoxigenic diarrhea with 2-substituted adenosine derivatives Methods of therapeutically treating individuals suffering from diarrhea comprising the step of administering to such individuals who are suffering from diarrhea, an effective amount of a 2-substituted adenine nucleotide or 2-substituted adenine nucleoside... | 10/06/1998 |
| 5817639 | Purine 4'-thioarabinonucleosides The present invention provides a novel purine 4'-thioarabinonucleoside represented by the following formula 1!: ##STR1## wherein B represents a purine base other than adenine. Also disclosed are a method for preparing the purine 4'-thioarabinonucle... | 10/06/1998 |
